ID

30934

Descripción

Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis; ODM derived from: https://clinicaltrials.gov/show/NCT00475865

Link

https://clinicaltrials.gov/show/NCT00475865

Palabras clave

Versiones (1)
  1. 4/7/18 4/7/18 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

4 de julio de 2018

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Multiple Sclerosis NCT00475865

Inglés

Eligibility Multiple Sclerosis NCT00475865

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
definite ms diagnosis according to mcdonald's criteria;
Descripción

Multiple Sclerosis

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0026769
relapsing clinical course, with or without progression;
Descripción

Clinical course Relapsing | Disease Progression | Disease Progression Absent

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0449259
UMLS CUI [1,2]
C0035020
UMLS CUI [2]
C0242656
UMLS CUI [3,1]
C0242656
UMLS CUI [3,2]
C0332197
expanded disability status scale [edss] less or equal to 5.5 (ambulatory);
Descripción

EDSS Ambulatory

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0451246
UMLS CUI [1,2]
C0439841
stable dose of glatiramer acetate [ga] for at least 26 weeks prior to the screening visit;
Descripción

Glatiramer acetate Dosage Stable

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0289884
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0205360
no onset of ms relapse in the preceding 60 days prior to randomization;
Descripción

Absence Onset of Multiple sclerosis relapse

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0332197
UMLS CUI [1,2]
C0332162
UMLS CUI [1,3]
C0856120
clinically stable for 4 weeks prior to randomization.
Descripción

Stable status Clinical

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0205360
UMLS CUI [1,2]
C0205210
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
other chronic disease of the immune system, liver function impairment or chronic pancreatic disease;
Descripción

Chronic disease of immune system | Liver Dysfunction | Pancreatic Disease chronic

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1290894
UMLS CUI [2]
C0086565
UMLS CUI [3,1]
C0030286
UMLS CUI [3,2]
C0205191
pregnant or nursing woman;
Descripción

Pregnancy | Breast Feeding

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
alcohol or drug abuse;
Descripción

Substance Use Disorders

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0038586
use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before enrollment;
Descripción

Cladribine | Mitoxantrone | Immunosuppressive Agents | Azathioprine | Cyclophosphamide | Cyclosporine | Methotrexate | MYCOPHENOLATE

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0092801
UMLS CUI [2]
C0026259
UMLS CUI [3]
C0021081
UMLS CUI [4]
C0004482
UMLS CUI [5]
C0010583
UMLS CUI [6]
C0010592
UMLS CUI [7]
C0025677
UMLS CUI [8]
C0883242
human immunodeficiency virus [hiv] positive status;
Descripción

HIV Seropositivity

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0019699
any known condition or circumstance that would prevent in the investigator's opinion compliance or completion of the study.
Descripción

Condition Preventing Compliance behavior | Condition Preventing Completion of clinical trial

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0348080
UMLS CUI [1,2]
C1292733
UMLS CUI [1,3]
C1321605
UMLS CUI [2,1]
C0348080
UMLS CUI [2,2]
C1292733
UMLS CUI [2,3]
C2732579
the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Descripción

Eligibility Criteria Additional

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1516637
UMLS CUI [1,2]
C1524062
Volver a la parte superior de la página

Similar models

Eligibility Multiple Sclerosis NCT00475865

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Multiple Sclerosis
Item
definite ms diagnosis according to mcdonald's criteria;
boolean
C0026769 (UMLS CUI [1])
Clinical course Relapsing | Disease Progression | Disease Progression Absent
Item
relapsing clinical course, with or without progression;
boolean
C0449259 (UMLS CUI [1,1])
C0035020 (UMLS CUI [1,2])
C0242656 (UMLS CUI [2])
C0242656 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
EDSS Ambulatory
Item
expanded disability status scale [edss] less or equal to 5.5 (ambulatory);
boolean
C0451246 (UMLS CUI [1,1])
C0439841 (UMLS CUI [1,2])
Glatiramer acetate Dosage Stable
Item
stable dose of glatiramer acetate [ga] for at least 26 weeks prior to the screening visit;
boolean
C0289884 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
Absence Onset of Multiple sclerosis relapse
Item
no onset of ms relapse in the preceding 60 days prior to randomization;
boolean
C0332197 (UMLS CUI [1,1])
C0332162 (UMLS CUI [1,2])
C0856120 (UMLS CUI [1,3])
Stable status Clinical
Item
clinically stable for 4 weeks prior to randomization.
boolean
C0205360 (UMLS CUI [1,1])
C0205210 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Chronic disease of immune system | Liver Dysfunction | Pancreatic Disease chronic
Item
other chronic disease of the immune system, liver function impairment or chronic pancreatic disease;
boolean
C1290894 (UMLS CUI [1])
C0086565 (UMLS CUI [2])
C0030286 (UMLS CUI [3,1])
C0205191 (UMLS CUI [3,2])
Pregnancy | Breast Feeding
Item
pregnant or nursing woman;
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Substance Use Disorders
Item
alcohol or drug abuse;
boolean
C0038586 (UMLS CUI [1])
Cladribine | Mitoxantrone | Immunosuppressive Agents | Azathioprine | Cyclophosphamide | Cyclosporine | Methotrexate | MYCOPHENOLATE
Item
use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before enrollment;
boolean
C0092801 (UMLS CUI [1])
C0026259 (UMLS CUI [2])
C0021081 (UMLS CUI [3])
C0004482 (UMLS CUI [4])
C0010583 (UMLS CUI [5])
C0010592 (UMLS CUI [6])
C0025677 (UMLS CUI [7])
C0883242 (UMLS CUI [8])
HIV Seropositivity
Item
human immunodeficiency virus [hiv] positive status;
boolean
C0019699 (UMLS CUI [1])
Condition Preventing Compliance behavior | Condition Preventing Completion of clinical trial
Item
any known condition or circumstance that would prevent in the investigator's opinion compliance or completion of the study.
boolean
C0348080 (UMLS CUI [1,1])
C1292733 (UMLS CUI [1,2])
C1321605 (UMLS CUI [1,3])
C0348080 (UMLS CUI [2,1])
C1292733 (UMLS CUI [2,2])
C2732579 (UMLS CUI [2,3])
Eligibility Criteria Additional
Item
the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
boolean
C1516637 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial